Researchers at Stanford have designed a molecule that flips a major lymphoma-driving protein from a growth signal into a trigger for cell death. Instead of simply blocking the protein's tumor-promoting activity, the molecule harnesses it to activate the cancer cell's built-in self-destruct machinery.
In mouse studies, the treatment completely eliminated aggressive human lymphoma tumors within 11 days. The results suggest a new strategy for converting oncogenic proteins into therapeutic liabilities, though further research will be needed to assess safety and efficacy in humans.